Early (operable) breast cancer is defined as tumours not more than five centimetres in diameter, with either impalpable or palpable but not fixed lymph nodes and with no evidence of distant metastases.1
Taxanes are a class of chemotherapy compounds that includes paclitaxel, docetaxel and abraxane. As antimicrotuble agents, taxanes inhibit the normal process of reorganisation of the microtubule network essential for cellular function, which leads to a disruption of mitosis (cell division). Taxanes can be used as part of adjuvant or neoadjuvant chemotherapy regimens to treat early (operable) breast cancer. Of the three types of taxanes, only paclitaxel and docetaxel have been investigated in the adjuvant setting.